Home › Alnylam Presents New Pre-Clinical Data On RNAi Therapeutics Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR)
 

Keywords :   


Alnylam Presents New Pre-Clinical Data On RNAi Therapeutics Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR)

2014-04-30 06:24:19| drugdiscoveryonline News Articles

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, recently announced the presentation of new pre-clinical data on RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR)

Tags: data treatment presents targeting

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.11MSX2
24.11CITY 1-13
24.11 Loveyoursself Soul DVD
24.11B787-8 1/400
24.11GIANT CONTEND SL1105
24.11HappySanrio characters Halloween
24.11
24.11emmi
More »